There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on vTv Therapeutics (VTVT) and Crispr Therapeutics AG (CRSP) with bullish sentiments.
vTv Therapeutics (VTVT)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on vTv Therapeutics, with a price target of $5. The company’s shares closed yesterday at $1.54, close to its 52-week low of $0.68.
Bernardino wrote:
“Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success.”
According to TipRanks.com, Bernardino has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.5% and a 28.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals Inc, Can-Fite BioPharma, and Seres Therapeutics.
vTv Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, a 322.1% upside from current levels. In a report released yesterday, Northland Securities also maintained a Buy rating on the stock with a $8 price target.
See today’s analyst top recommended stocks >>
Crispr Therapeutics AG (CRSP)
Needham analyst Alan Carr maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $62. The company’s shares closed yesterday at $37.25.
According to TipRanks.com, Carr is a 4-star analyst with an average return of 2.7% and a 40.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $61.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
